MUSCLE-INVASIVE BLADDER CANCER

This phase 3 trial tests whether a combination of enfortumab vedotin and pembrolizumab, given before and after bladder removal surgery, works better than standard chemotherapy for muscle-invasive bladder cancer. About 800 participants will be randomly assigned to one of the two t…

This pilot study tested whether adding the anti-inflammatory drug celecoxib (Celebrex) to standard chemotherapy before bladder cancer surgery is safe and affects tumor genes. 22 people with muscle-invasive bladder cancer took part. The goal was to see how the treatment changed ca…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. About 900 participants took part. The goal was to s…

This study tested a new way to treat muscle-invasive bladder cancer by tailoring therapy based on each patient's tumor genetics. After initial chemotherapy, patients with a good response could avoid bladder removal and instead opt for active monitoring or less invasive treatments…

This study tested a drug called sacituzumab govitecan given before bladder removal surgery in 44 people with muscle-invasive bladder cancer who could not take or refused standard cisplatin chemotherapy. The goal was to see if the drug could completely eliminate the tumor by the t…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (gemcitabine and cisplatin) could shrink tumors more effectively before bladder cancer surgery. 39 people with muscle-invasive bladder cancer received the combination before …

This completed study tested a three-step treatment for muscle invasive bladder cancer: chemotherapy, then a minimally invasive surgery to remove the tumor, followed by radiation. The goal was to treat the cancer while keeping the bladder intact, which could improve quality of lif…

This study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combinations were safest and most effective at shrinking tumors or slowing the disease. Participants…

This study tested a weekly, higher-dose radiation schedule (hypofractionated radiotherapy) for people with muscle-invasive bladder cancer who cannot have standard daily radiation or surgery. It included 65 participants and compared standard radiation planning with a newer 'adapti…

This pilot study tested whether a new radioactive tracer called 18F-fluciclovine, used with a PET/CT scan, can better determine the extent of muscle invasive bladder cancer before surgery. Sixteen participants with bladder cancer received the tracer and scan before their planned …

This study tested how well a special MRI scan (called multiparametric MRI) can tell if bladder cancer has grown into the muscle layer of the bladder. Researchers used a scoring system called VI-RADS to interpret the scans. The study included 60 people with bladder masses who were…

This study tested whether a special type of PET/MR scan (using radioactive water) can accurately tell if bladder cancer has been completely eliminated by chemotherapy. 13 patients with muscle-invasive bladder cancer were scanned before and after chemotherapy, and the results were…

This study looked at whether FDG-PET CT scans can more accurately stage muscle invasive bladder cancer compared to standard CT scans. Researchers reviewed records of 130 patients who had PET CT scans at diagnosis. The goal was to see if PET CT better detects cancer spread to lymp…